MacroGenics, Inc.

NASDAQ:MGNX

Biotechnology

Healthcare
$1.97 +2.02%

+$0.08 today

Market cap
$125.90M
Beta
1.20
P/E (TTM)
-3.6
EPS (TTM)
-$1.11
52W Low $1.19High $4.64

Volume 0.72M

Average 0.98M

MGNX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

MacroGenics, Inc.NASDAQ: MGNX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.65M fell 39.7% year over year, ahead of the -55.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at -11.3% a year.

Context

  • Stock-based compensation amounted to 9.6% of revenue in FY2025, down 10.3 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -39.7% holds above the trailing-twelve-month pace of -55.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.65M-0.6% QoQ
Last fiscal yearDec 2025
$14.29M-51.5% YoY
LTMMar 2026
$12.55M-55.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.7%——
1 year-51.5%——
3-year CAGR-11.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
14.29M USD
Year-over-year change
-51.5%
4-year CAGR
-11.3%

Stock-Based Compensation vs competitors

How MGNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -55.6% is the 9th highest of 11, against a peer median of -7.9%.
  • Stock-based compensation amounts to 8.0% of revenue for MGNX, versus a peer median of 768.9%.
MGNX Competitors
Stock-Based Compensation for MGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$14.24M USD-76.6%-23.8%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$9.87M USD-8.9%+0.8%138.2%
STTKShattuck Labs, Inc.LTM Mar 2026$7.69M USD-12.5%+2.7%768.9%
CLNNClene Inc.LTM Mar 2026$7.45M USD-5.5%-9.2%5559.7%
COYACoya Therapeutics, Inc.LTM Mar 2026$5.41M USD+63.4%+174.5%68.1%
CNTBConnect Biopharma Holdings LimitedFY2025$3.73M USD-44.6%+54.6%5821.9%
IFRXInflaRx N.V.LTM Mar 2026€2.48M EUR-152.9%—8455.2%
OVIDOvid Therapeutics Inc.LTM Mar 2026$2.41M USD-6.9%-9.8%33.9%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$2.28M USD+4.3%——
CNTXContext Therapeutics Inc.LTM Mar 2026$1.45M USD+61.5%+10.9%—
Peer median (excluding MGNX) —-7.9%+1.7%768.9%

Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(202.12M)(119.76M)(9.06M)(66.97M)(74.62M)
Depreciation & Amortization11.26M11.87M9.65M7.54M5.52M
Deferred Income Tax00000
Stock-Based Compensation23.13M20.44M18.37M29.44M14.29M
Change in Working Capital17.57M(6.13M)53.32M1.39M(28.33M)
Accounts Receivables12.7M(45.84M)45.86M6.06M(9.06M)
Inventory(6.42M)55K230K(2.19M)(7.91M)
Accounts Payables7.13M(10.86M)1.28M(1.53M)(280K)
Other Working Capital4.17M50.51M5.95M(948K)(11.08M)
Other Non-Cash Items6.33M6.63M(150.48M)(39.78M)2.1M
Operating Cash Flow(143.83M)(86.96M)(78.21M)(68.37M)(81.04M)
Capital Expenditures(6.2M)(3.62M)(1.76M)(3.71M)(1.91M)
Acquisitions (Net)0064K011K
Purchases of Investments(231.21M)(120.6M)(239.68M)(77.18M)(208.34M)
Sales of Investments200.8M194.94M161.3M190.03M96.14M
Other Investing Activities00040.16M0
Investing Cash Flow(36.61M)70.72M(80.08M)149.3M(114.1M)
Debt Repayment00(157K)00
Common Stock Issued117.82M1.09M1.17M3.44M129K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities4.96M574K149.35M960K69.39M
Financing Cash Flow122.78M1.66M150.36M960K69.51M
Effect of Forex Changes00000
Net Change in Cash(57.66M)(14.59M)(7.93M)81.88M(125.62M)
Free Cash Flow(150.03M)(90.58M)(79.97M)(72.08M)(82.95M)

MacroGenics, Inc.

NASDAQ:MGNX

Intrinsic Alpha fair value

Locked

Current Price

$1.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.